---
title: "Lorusso Lifts Price Target to $65 and Reiterates Buy on Strong Arcalyst Momentum and Upside Potential"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284429058.md"
description: "Analyst Nicholas Lorusso from TD Cowen has reiterated a Buy rating on Kiniksa Pharmaceuticals, raising the price target from $60 to $65 due to strong momentum for Arcalyst. The drug has exceeded quarterly expectations and shown growth in physician adoption. Management has also increased 2026 revenue guidance, indicating a positive outlook. Lorusso's confidence in peak sales for recurrent pericarditis and upcoming Phase II data for KPL-387 further supports his bullish stance. Wedbush also maintains a Buy rating with a $58 price target."
datetime: "2026-04-28T16:35:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284429058.md)
  - [en](https://longbridge.com/en/news/284429058.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284429058.md)
---

# Lorusso Lifts Price Target to $65 and Reiterates Buy on Strong Arcalyst Momentum and Upside Potential

Analyst Nicholas Lorusso from TD Cowen maintained a Buy rating on Kiniksa Pharmaceuticals and increased the price target to $65.00 from $60.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Nicholas Lorusso has given his Buy rating due to a combination of factors including Arcalyst’s consistently strong performance and an improved outlook for its long‑term revenue potential. Arcalyst once again exceeded quarterly expectations despite normal seasonal pressure, extended its multi‑year growth streak, and demonstrated expanding physician adoption and repeat prescribing trends that still tap only a portion of the eligible market.

Building on this operational momentum, management raised 2026 Arcalyst revenue guidance above prior levels and consensus, while physician survey work signals that even this outlook may be conservative. Reflecting higher confidence in peak recurrent pericarditis sales, Lorusso increased his DCF-based price target from $60 to $65 and sees additional upside from upcoming, relatively derisked Phase II data for KPL-387, reinforcing his positive stance on the stock.

In another report released on April 16, Wedbush also maintained a Buy rating on the stock with a $58.00 price target.

### Related Stocks

- [KNSA.US](https://longbridge.com/en/quote/KNSA.US.md)

## Related News & Research

- [Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Raised to Hold at Zacks Research](https://longbridge.com/en/news/287057945.md)
- [How Kiniksa’s Shift To Profitability And Higher Revenue At Kiniksa Pharmaceuticals International (KNSA) Has Changed Its Investment Story](https://longbridge.com/en/news/284404462.md)
- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)
- [EXCLUSIVE-FDA drug center head expected to leave after commissioner's exit, sources say](https://longbridge.com/en/news/286589761.md)
- [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md)